Aquestive Therapeutics, Inc. Litigation

Apr 7, 2023

Voluntary Dismissal

The plaintiff in this action has chosen not to proceed with the case. Once a case is voluntary dismissed, the courts will usually close the case and no further action will be taken.

Mar 14, 2023

Motion to Dismiss Denied in Part

The court has determined that plaintiffs have adequately alleged some of their claims, but have failed to adequately allege other claims. The judge has therefore denied in part the motion to dismiss filed by defendants and written an order stating which claims are dismissed and which remain. The case will proceed and parties will litigate the remaining claims.

Aug 16, 2021

Motion to Dismiss

After reviewing the complaint(s) filed by plaintiffs, defendants have filed a motion requesting that the court dismiss some or all of the plaintiffs' claims. In a motion to dismiss, defendants might challenge the validity of plaintiffs' claims or adequacy of plaintiffs' pleadings. Once a motion to dismiss is filed, the judge will make a decision on whether part or all of the case should be dismissed or the case can proceed as alleged.

Jun 25, 2021

First Amended Complaint

A new complaint has been filed on behalf of certain investors in Aquestive Therapeutics, Inc.. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.

May 7, 2021

Scheduling Order

May 6, 2021

Appointment of Lead Plaintiff

The court has appointed a lead plaintiff to represent the interests of investors in the lawsuit. The lead plaintiff works with the attorneys handling the case, helps oversee the litigation, and represents the interests of the proposed class.

Mar 1, 2021

First Filed Complaint

A securities fraud class action complaint has been filed on behalf of certain investors in Aquestive Therapeutics, Inc..